Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis

BackgroundErdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on a phase 2 clinical trial, revealing a 40% response rate, and 13.8 mo...

Full description

Bibliographic Details
Main Authors: Keren Rouvinov, Eran Levanon, Avivit Peer, Michal Sarfaty, David Sarid, Victoria Neiman, Eduard Grikshtas, Eli Rosenbaum, Igal Kushnir, Barak Talmor, Michael Friger, Yonaton Zarbiv, Eli Gez, Hadas Dresler, Walid Shalata, Amichay Meirovitz, Noa Shani Shrem, Alexander Yakobson, Wilmosh Mermershtain, Daniel Keizman
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
erdafitinib
metastatic urothelial carcinoma
treatment
real-world analysis
fibroblast growth factor receptor (FGFR) inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1151701/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1151701/full

Similar Items